Diabetic Neuropathy

Diabetic Neuropathy Market by Treatment Type (Drugs, Physiotherapy), Disorder Type (Autonomic Neuropathy, Focal Neuropathy, Peripheral Neuropathy), Distribution channel - Global Forecast 2024-2030

360iResearch Analyst
SPEAK TO ANALYST? OR FACE-TO-FACE MEETING?
Want to know more about the diabetic neuropathy market or any specific requirement? Ketan helps you find what you're looking for.
DOWNLOAD A FREE PDF
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[181 Pages Report] The Diabetic Neuropathy Market size was estimated at USD 3.50 billion in 2023 and expected to reach USD 3.72 billion in 2024, at a CAGR 6.37% to reach USD 5.40 billion by 2030.

Diabetic Neuropathy Market
To learn more about this report, request a free PDF copy

Diabetic neuropathy is a medical condition that damages the nerve and occurs in patients who have diabetes. High blood sugar (glucose) can damage nerves throughout the body, and diabetic neuropathy most frequently impacts nerves in the legs and feet. The increasing need for effective treatment for diabetic neuropathy, diagnosis of diabetes, and several government initiatives are the major driving factors for the growth of the diabetic neuropathy market. In addition, the growing awareness about diabetic neuropathy, increased healthcare spending, and a rise in pharmaceutical R&D spending contribute to developing novel drugs and systems for treating diabetic neuropathy. However, the high cost of medications used to treat diabetic neuropathy and the availability of alternative therapies may limit their use by diabetic patients. Production of advanced drug delivery systems and rising research in diabetic neuropathy are leading to the development of a breakthrough system for the effective management of diabetic neuropathy conditions, accelerating their use by patients in the forecast period.

Diabetic Neuropathy Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function

Drugs are used in the pharmacological treatment of diabetic neuropathy for alleviating pain and stabilizing nerve function. Pregabalin (Lyrica) and gabapentin (Neurontin) are popular anticonvulsant drugs for managing nerve pain in diabetic neuropathy patients. Among opioids, Tramadol (Ultram) is a centrally-acting opioid analgesic prescribed for moderate to severe pain associated with diabetic neuropathy. Physiotherapy, also known as physical therapy, is a non-pharmacological treatment that can help diabetic neuropathy patients improve their functional abilities and alleviate pain. Regular exercise and strengthening programs supervised by a certified physiotherapist can help improve muscle strength, balance, and endurance in diabetic neuropathy patients. Physiotherapy is often preferred to avoid side effects or contraindications.

Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy

Autonomic neuropathy affects the autonomic nervous system, which controls the involuntary functions of internal organs. Patients with this condition experience irregular heartbeat, urinary problems, digestive issues, and sexual dysfunction. Based on individual needs, treatments include medications to regulate blood pressure and heart rate, drugs for gastrointestinal motility, and medications to treat erectile dysfunction. Focal neuropathy is a disorder that affects a single nerve or group of nerves, causing severe pain or weakness localized in specific body parts such as hands, feet, or torso. The treatment addresses the underlying cause, such as compression or entrapment, including splinting or bracing for carpal tunnel syndrome or surgical intervention for severe cases. Peripheral neuropathy is the most common type, affecting the nerves of arms, hands, legs, and feet. Symptoms include numbness, tingling, pain, and weakness. Treatment preferences depend on individual needs, including over-the-counter pain relievers and prescription medications. Proximal neuropathy primarily affects the hip, buttock, or thigh muscles with symptoms such as severe pain and muscle weakness.

Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management

Patients with diabetic neuropathy prefer clinics for convenience, affordability, and accessibility as they provide specialized care through a team of experts, including endocrinologists, podiatrists, and diabetes educators. Hospitals serve as comprehensive care providers for diabetic neuropathy patients requiring more extensive treatment or emergency interventions due to severe complications such as infections or ulcers. They offer access to equipment and multidisciplinary teams with expertise in treating complex cases. Online pharmacies have emerged as a convenient distribution channel for medications prescribed for diabetic neuropathy management, such as pain relievers, anti-seizure medications, and antidepressants. Patients prefer online pharmacies due to their ease of use, discreet delivery options, and competitive pricing compared to retail pharmacies. Retail pharmacies are popular for obtaining medications and over-the-counter supplements to manage diabetic neuropathy. They offer the advantage of face-to-face interaction with pharmacists who can provide personalized advice, medication management support, and access to a wide range of products.

Regional Insights

The Americas has a significant market in diabetic neuropathy due to the presence of a rising number of diabetic patients and increasing awareness related to diabetes disorders. Approvals from the FDA for new product development and ongoing research activities for developing novel and effective drugs are major growth factors in the Americas region. The Asia-Pacific region represents a growing landscape for the global diabetic neuropathy market due to increasing R&D activities in drug development. Several start-ups focusing on developing diabetic neuropathy treatments in the APAC region have contributed to the market growth. Government support to raise awareness regarding diabetes management and increased research and development of novel drugs and systems for relieving pain and efficient management of diabetic neuropathy conditions are creating the immense potential for the deployment of diabetic neuropathy drugs and systems in the EMEA region. Additionally, the introduction of innovative treatments and drug delivery systems is expected to contribute to the growth of the diabetic neuropathy market worldwide.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Diabetic Neuropathy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Diabetic Neuropathy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain

    NeuraLace Medical, Inc. announced the completion of enrollment in the AT-PDN study, which involved randomizing 70 patients into treatment and sham groups. This development represents a potential breakthrough in the treatment of PDN, with the potential to benefit millions of patients. [Published On: 2023-09-11]

  • GBP 1.4 million Awarded to Create early test for Diabetic Peripheral Neuropathy

    Scientists from the University of Liverpool and Manchester Metropolitan University have received funding of GBP 1.4 million to develop an early test for Diabetic Peripheral Neuropathy (DPN). The project involves collaboration between university investigators and partners such as Aintree University Hospital and Weill Cornell Medicine, funded by the Engineering & Physical Sciences Research Council (EPSRC) for over GBP 1 million. [Published On: 2023-06-07]

  • Horizon Therapeutics PLC announced FDA approval of an update to the indication language for TEPEZZA (teprotumumab-trbw) to specify its use in thyroid eye disease (TED) patients regardless of disease activity or duration

    Horizon Therapeutics PLC, a biopharmaceutical company focused on creating innovative medicines to enable people to live better lives, received an update from the United States Food and Drug Administration (FDA) regarding the approval of their drug, Tepezza. This drug has already been approved for treating thyroid eye disease and is now considered for treating diabetic neuropathy as well. [Published On: 2023-04-14]

Key Company Profiles

The report delves into recent significant developments in the Diabetic Neuropathy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AdventHealth, Alkem Labs, Astellas Pharma Inc., AstraZeneca PLC, Bauerfeind AG, Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Collegium Pharmaceutical, Inc., Daiichi Sankyo Company, Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Grünenthal GmbH, Harmonium Pharma s.r.l., Lupin Limited, Medtronic PLC, Merck KGaA, NeuroMetrix, Inc., Nevro Corp., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Praetego, LLC, Regenacy Pharmaceuticals, Inc., Sanofi S.A., Stem Cell Care India, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Trevena, Inc., Vertex Pharmaceuticals Incorporated, Viatris Inc., and Winsantor, Inc..

Market Segmentation & Coverage

This research report categorizes the Diabetic Neuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Type
    • Drugs
      • Analgesics
        • Non-Steroidal Anti-Inflammatory Drugs
        • Opioids
        • Topical
      • Anticonvulsants
        • Gabapentin
        • Pregabalin
        • Topiramate
      • Antidepressant
        • Serotonin & Norepinephrine Reuptake Inhibitors
        • SSRIs
        • TCAs
    • Physiotherapy
  • Disorder Type
    • Autonomic Neuropathy
    • Focal Neuropathy
    • Peripheral Neuropathy
    • Proximal Neuropathy
  • Distribution channel
    • Clinics
    • Hospitals
    • Online Pharmacy
    • Retail Pharmacy

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Diabetic Neuropathy Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Diabetic Neuropathy Market?
  3. What are the technology trends and regulatory frameworks in the Diabetic Neuropathy Market?
  4. What is the market share of the leading vendors in the Diabetic Neuropathy Market?
  5. Which modes and strategic moves are suitable for entering the Diabetic Neuropathy Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Diabetic Neuropathy Market, by Treatment Type
  7. Diabetic Neuropathy Market, by Disorder Type
  8. Diabetic Neuropathy Market, by Distribution channel
  9. Americas Diabetic Neuropathy Market
  10. Asia-Pacific Diabetic Neuropathy Market
  11. Europe, Middle East & Africa Diabetic Neuropathy Market
  12. Competitive Landscape
  13. Competitive Portfolio
  14. List of Figures [Total: 22]
  15. List of Tables [Total: 648]
  16. List of Companies Mentioned [Total: 34]
Innovations Navigating the Challenges of Diabetic Neuropathy Management
September 14, 2023
INSIGHT
Innovations Navigating the Challenges of Diabetic Neuropathy Management
In the dynamic world of medical advancements, innovative solutions are emerging to transform the landscape of diabetic neuropathy management caused by prolonged high blood sugar levels

Diabetic neuropathy, a common complication of diabetes, poses significant challenges to those living with the condition. This debilitating condition arises due to prolonged high blood sugar levels, which damage nerves throughout the body. The result? A symptom that can impact a person's quality of life.

However, in the dynamic world of medical advancements, innovative solutions are emerging to transform the landscape of diabetic neuropathy management. The innovation that's capturing attention is the development of wearable devices equipped with sensors and smart algorithms that can monitor temperature, pressure, and vibration sensation in extremities.

Another groundbreaking avenue lies in the world of regenerative medicine. Researchers are exploring stem cell therapy to repair damaged nerves. Early clinical studies have shown results in improving nerve function and reducing pain. While this area of innovation is still in its infancy, it holds the promise of revolutionizing neuropathy treatment in the future.

Artificial intelligence (AI) is also making its mark in diabetic neuropathy management. AI-powered diagnostic tools can analyze symptoms, medical history, and test results to predict the probability of developing neuropathy.

From wearable sensors to regenerative therapies, the future holds the potential for more effective treatments and enhanced quality of life for those affected by neuropathy.

Understanding the Government Initiatives for the Management of Diabetic Neuropathy
June 26, 2023
BLOG
Understanding the Government Initiatives for the Management of Diabetic Neuropathy
Diabetes is a chronic condition affecting millions worldwide, leading to various complications. Diabetic neuropathy is one such severe complication that occurs due to chronic high blood sugar levels. It affects the peripheral and autonomic nervous system, causing loss of sensation, severe pain, and other debilitating symptoms that negatively impact the patient's quality of life. In response, several government initiatives aim to manage diabetic neuropathy effectively and minimize its impact.

National Diabetes Prevention Program:

The National Diabetes Prevention Program is an evidence-based lifestyle change program managed by the Centers for Disease Control and Prevention (CDC) that aims to halt the progression of prediabetes to type 2 diabetes by promoting a healthy lifestyle, increasing physical activity, and encouraging healthy eating habits. Patients diagnosed with prediabetes are more likely to develop neuropathy and other complications, and thus, this program can prevent this.

Diabetes Action Plan:

The Diabetes Action Plan is a set of guidelines developed by the US Department of Health and Human Services to improve the management of diabetes and its complications. The plan focuses on educating patients and care providers, improving access to care, and increasing the use of evidence-based practices. This initiative ensures that diabetic neuropathy patients receive the necessary education and healthcare they need to manage their condition effectively.

Medicare Advantage:

In 2021, the Centers for Medicare and Medicaid Services launched the Medicare Advantage Value-Based Insurance Design Model to support Medicare Advantage plans in offering more comprehensive care coverage for patients with chronic conditions like diabetes. This initiative aims to promote value-based care with a focus on outcomes to reduce the burden on patients and improve care quality for those living with diabetic neuropathy.

Diabetes Self-Management Education (DSME) and Support:

DSME is a critical initiative that aims to empower patients with self-management skills to better manage their diabetes and its complications. It is an evidence-based education initiative developed by the CDC that focuses on teaching self-management strategies, promoting healthy lifestyle changes, and encouraging patients to be active participants in their healthcare. DSME empowers diabetic neuropathy patients to take control of their health and well-being.

Telehealth Services:

Finally, during the COVID-19 pandemic, telehealth services have played a vital role in managing diabetic neuropathy. Telehealth services offer remote, secure, and confidential access to healthcare services for patients with diabetes, reducing the risk of exposure to the virus while providing much-needed care. This initiative promotes patient safety, allowing those with diabetic neuropathy to continue receiving necessary healthcare services without the risk of exposure.

The government initiatives for the management of diabetic neuropathy have greatly impacted healthcare outcomes for patients living with diabetes. These initiatives aimed at preventing diabetic neuropathy, empowering patients with self-management skills, and providing much-needed care are vital in managing the condition and reducing its impact. It is essential for healthcare providers, patients, and policymakers to continue to support and invest in these initiatives for better healthcare outcomes for diabetic neuropathy patients.

Frequently Asked Questions
  1. How big is the Diabetic Neuropathy Market?
    Ans. The Global Diabetic Neuropathy Market size was estimated at USD 3.50 billion in 2023 and expected to reach USD 3.72 billion in 2024.
  2. What is the Diabetic Neuropathy Market growth?
    Ans. The Global Diabetic Neuropathy Market to grow USD 5.40 billion by 2030, at a CAGR of 6.37%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.